# CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) · Edgar & Edgarette company card

> Creative Medical Technology Holdings (CELZ) saw revenue fall 45.5% in FY2025 to $0 million, operating margin -102380% against a -15.8% median for biological products, (no diagnostic substances), equity 96.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1187953 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CELZ) · [JSON](https://www.pops4.com/boards/company/CELZ.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $6,000 |
| Revenue growth, 1 year | -45.5% |
| Revenue growth per year | -48.9% |
| Operating margin | -102380.2% (prior year -52216.9%) |
| Net margin | -99916.8% |
| Operating cash flow | −$6M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $7M |
| Long-term debt | — |
| Total assets | $8M |
| Total equity | $8M |
| Equity ÷ assets | 96.2% |
| Return on equity | -79.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -1.08 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$5.9M in FY2025); operating loss: a margin of -102380.2% in FY2025; revenue is hard to predict: its 80% range is ±59%

## Edgarette's reading

Exposure: revenue $6K (FY2025). Experience: revenue down 45.5% on the year, down 48.9% a year over 4 years; operating margin -102380.2%, down from -52216.9%. Soundness: equity 96.2% of assets, return on equity -79.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1K and $6K next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1K to $6K. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -102380.2% against a -15.8% median; growth -45.5% against 21.4%.

Range logged 2026-09-28, receipt 58f40fe57e9ac279, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-07-02 ([filing](https://www.sec.gov/Archives/edgar/data/1187953/000147793226004165/0001477932-26-004165-index.htm))

## Recent filings

- DEF 14A · filed 2026-11-10 · [filing](https://www.sec.gov/Archives/edgar/data/1187953/000147793226006814/0001477932-26-006814-index.htm)
- 10-Q · filed 2026-11-06 · [filing](https://www.sec.gov/Archives/edgar/data/1187953/000147793226006758/0001477932-26-006758-index.htm)
- 8-K · filed 2026-09-25 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1187953/000147793226005805/0001477932-26-005805-index.htm)
- 8-K · filed 2026-08-31 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1187953/000147793226005329/0001477932-26-005329-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/1187953/000147793226004779/0001477932-26-004779-index.htm)
- DEF 14A · filed 2026-07-14 · [filing](https://www.sec.gov/Archives/edgar/data/1187953/000147793226004302/0001477932-26-004302-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001187953.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1187953

## Cite

POPS4, Edgar & Edgarette: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) company card, from the company's own SEC filings, accessed 2026-11-12, https://www.pops4.com/boards/company/CELZ. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.